The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Richard Schilsky to leave role as PI of ASCO’s TAPUR study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Richard L. Schilsky will be leaving his role as inaugural principal investigator of the American Society of Clinical Oncology-led Targeted Agent and Profiling Utilization Registry study after a decade of leadership.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
In Brief

Darrow Zeidenstein named chief development officer at ACS

Darrow Zeidenstein was named chief development officer at the American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. In this role, Zeidenstein will lead the organization’s development efforts, overseeing all aspects of resource generation, including corporate partnerships, philanthropy, planned giving, Discovery Shops, community-based fundraising, and revenue-generating field operations. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account